5 Pharmaceutical preparations for the treatment of chronic diseases, namely, alpha-1 antitrypsin deficiency, moderate to severe persistent asthma, pulmonary arterial hypertension, respiratory syncytial virus, chronic, moderate to severe plaque psoriasis, hereditary tyrosinemia type 1, autoimmune disorders and primary immune deficiencies, growth hormone deficiency, Fabry disease, rheumatoid arthritis, psoriatic arthritis, hemophilia, Gaucher disease, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, multiple sclerosis, hypomobility associated with advanced Parkinson's disease, MPS 1, severe combined immunodeficiency disease, chronic granulomatour disease, severe malignant osterpetrosis; pharmaceutical preparations for use as blood clotting agents used in the control of hemophilia; pharmaceutical preparations for the treatment of chronic diseases, namely disorders requiring intravenous immunoglobulin therapy; pharmaceutical preparations for the treatment of hemophilia